What should you know about kadcyla chemo?

Kadcyla combines an antibody that recognises the HER2 protein with a chemotherapy medicine. After binding to HER2-positive cancer cells, it can help deliver the chemotherapy component to those cells. It is not interchangeable with every chemotherapy regimen, and the reason for prescribing it depends on the cancer’s HER2 results, stage, previous treatment, and current health. Treatment is given through a vein at an oncology unit on a schedule set by the treating team.

Before each infusion, tell the team about new symptoms, medicines, supplements, allergies, and any chance of pregnancy. Blood tests help check blood counts and liver function. Your team may also assess heart function before and during treatment because HER2-directed medicines can affect the heart. Report unusual tiredness, nausea, appetite change, bruising, headache, or pain rather than stopping treatment yourself. Ask how to manage side effects and when blood tests or the next infusion are due.

Contact the oncology team urgently for fever, chills, sudden breathing difficulty, chest pain, fainting, a fast or irregular heartbeat, yellowing of the skin, dark urine, unusual bleeding, or severe weakness. During or shortly after an infusion, tell staff immediately about flushing, rash, swelling, wheezing, dizziness, or back pain. These can signal an infusion reaction or another problem needing prompt assessment.

Ask why Kadcyla is recommended for your HER2 result, what benefit the team is aiming for, and how long the planned course may last. Ask which blood tests and heart checks are needed, which medicines may interact with it, and how side effects will be treated. Confirm the contact number for symptoms between infusions.